Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.
Videos
A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.
A look toward the future treatment of advanced renal cell carcinoma.
Expert perspectives on the clinical utility of lenvatinib plus pembrolizumab as a frontline combination for advanced renal cell carcinoma.
Robert J. Motzer, MD, discusses dosing strategies to mediate toxicities and maximize efficacy from the frontline combination of lenvatinib plus pembrolizumab for renal cell carcinoma.
The shortcomings physicians face in combatting CLL (chronic lymphocytic leukemia) are discussed, in addition to what the high-level updates from the ELEVATE-RR press release may reveal regarding future treatments for CLL.
Jennifer R. Brown, MD, PhD, suggests alternative treatments for patients who experience severe adverse-events from ibrutinib.
Citing results from recent trials, Jennifer R. Brown, MD, PhD, compares patient tolerability levels of ibrutinib, zanubrutinib, and acalabrutinib.
Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).
Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).
A leading authority in multiple myeloma comments on the future of belantamab mafodotin, such as combination therapy based on the DREAMM 5 and DREAMM 8 trials.
Sagar Lonial, MD, FACP, emphasizes the importance of partnering with eye care specialists to manage optical toxicities of patients taking belantamab mafodotin.
A key opinion leader in medical oncology reviews optical and hematological toxicities of belantamab mafodotin and discusses how to mitigate adverse events.
An expert in multiple myeloma considers rationale for targeting BCMA and discusses recent FDA approval of belantamab mafodotin based on the DREAMM 2 trial.
Sagar Lonial, MD, FACP, discusses factors to consider when selecting later lines of therapy for patients with triple-class refractory multiple myeloma (MM).
Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.
Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.
A comprehensive review of the efficacy and safety data from the phase 3 CLEAR trial (Study 307/KEYNOTE-581) for the frontline treatment of advanced renal cell carcinoma.
An expert in genitourinary oncology, Robert J. Motzer, MD, reviews the recent historic advances in frontline combinations for the treatment of advanced clear-cell renal cell carcinoma.
Tycel J. Phillips, MD, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma.
The future of ovarian cancer treatment is discussed through a summary of current treatment options, future directions, and a review the unmet needs facing patients and physicians today.
Shannon Westin, MD, reviews essential treatment considerations for physicians when subscribing niraparib.
The utilization and effectiveness of using PARP inhibitors in treating ovarian cancer is considered.
Shannon Westin, MD, discusses niraparib and its relation to the design, efficacy, and practical implications of the PRIMA trial.
Systemic frontline therapy options are explored through the lens of treating ovarian cancer.
Shannon Westin, MD, analyzes the role of molecular testing in newly diagnosed ovarian cancer.
Shannon Westin, MD, discusses the prognosis of the case patient and the general prognosis and treatment options for ovarian cancer patients overall.
Shannon Westin, MD, introduces the case patient and highlights the diagnosis and treatment path to combat stage IV ovarian cancer.
Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.